Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
121.16(c) 122.7(c) 120.26(c) 121.51(c) 123.79 Last
723 327 535 591 481 661 654 771 517 026 Volume
+1.08% +1.27% -1.99% +1.04% +1.88% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 3 070 M - -
Net income 2021 -121 M - -
Net Debt 2021 4 988 M - -
P/E ratio 2021 -2 430x
Yield 2021 -
Sales 2022 3 670 M - -
Net income 2022 571 M - -
Net Debt 2022 3 970 M - -
P/E ratio 2022 16,2x
Yield 2022 -
Capitalization 7 609 M 7 609 M -
EV / Sales 2021 4,10x
EV / Sales 2022 3,16x
Nbr of Employees 1 940
Free-Float 97,4%
More Financials
Company
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both... 
Sector
Pharmaceuticals
Calendar
12/06 | 01:00pmPresentation
More about the company
Ratings of Jazz Pharmaceuticals plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about JAZZ PHARMACEUTICALS PLC
12/02Jazz Pharmaceuticals to Present from Expanding Neuroscience Portfolio Epidiolex (cannab..
AQ
12/01Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca (lurbinect..
AQ
12/01Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluati..
AQ
11/30Jazz Pharma Doses First Patient in Late-Stage Combo Trial of Small Cell Lung Cancer Mai..
MT
11/30Jazz Pharmaceuticals Announces First Patient Enrolled in IMforte Phase 3 Trial Evaluati..
CI
11/30Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (lu..
AQ
11/30Jazz Pharmaceuticals plc and PharmaMar Announces Commercial Availability in Canada of Z..
CI
11/22JAZZ PHARMACEUTICALS : Corporate Overview
PU
11/19National Institute for Health and Care Excellence (NICE) Issues Positive Guidance for J..
AQ
11/19Goldman Sachs Reinstates Jazz Pharmaceuticals at Buy With $198 Price Target
MT
11/18JAZZ PHARMACEUTICALS : Corporate Overview
PU
11/18National Institute for Health and Care Excellence Issues Positive Guidance for Jazz Pha..
CI
11/09JAZZ : Q3 Earnings Snapshot
AQ
11/09Jazz Reports Higher Q3 Earnings, Beats Estimates; Updates 2021 Forecast
MT
11/09JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND RAISES FULL YEA..
PU
More news
News in other languages on JAZZ PHARMACEUTICALS PLC
11/30Jazz Pharma administre le premier patient d'un essai combiné de stade avancé portant su..
11/09Jazz annonce des bénéfices plus élevés au troisième trimestre, dépasse les estimations ..
11/09Earnings Flash (JAZZ) JAZZ PHARMACEUTICALS affiche un chiffre d'affaires de 838,1 milli..
11/09GUIDANCE : (JAZZ) JAZZ PHARMACEUTICALS prévoit une fourchette de bénéfices par action pour..
11/09Jazz Pharmaceuticals plc revoit à la hausse ses prévisions de bénéfices pour l'ensemble..
More news
Analyst Recommendations on JAZZ PHARMACEUTICALS PLC
More recommendations
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | JAZZ | IE00B4Q5ZN47 | MarketScreener
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 121,51 $
Average target price 202,74 $
Spread / Average Target 66,8%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC-26.38%7 469
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321